Plasmacytoid Dendritic Cells: Bring a Glimmer of Hope for Patients with Lymphangioleiomyomatosis.
作者信息
Du Heng, Liu Heng-Jia
机构信息
Division of Pulmonary and Critical Care Medicine Brigham and Women's Hospital Boston, Massachusetts.
Centre for Infection Immunity and Cancer Zhejiang University-University of Edinburgh Institute Haining, Zhejiang, China.
出版信息
Am J Respir Cell Mol Biol. 2024 Nov;71(5):503-504. doi: 10.1165/rcmb.2024-0266ED.
Abstract
摘要
相似文献
1
Plasmacytoid Dendritic Cells: Bring a Glimmer of Hope for Patients with Lymphangioleiomyomatosis.
Am J Respir Cell Mol Biol. 2024 Nov;71(5):503-504. doi: 10.1165/rcmb.2024-0266ED.
2
Plasmacytoid Dendritic Cells Mediate CpG-ODN-induced Increase in Survival in a Mouse Model of Lymphangioleiomyomatosis.
Am J Respir Cell Mol Biol. 2024 Nov;71(5):519-533. doi: 10.1165/rcmb.2023-0410OC.
3
Plasmacytoid dendritic cells and memory T cells infiltrate true sequestrations stronger than subligamentous sequestrations: evidence from flow cytometric analysis of disc infiltrates.
Eur Spine J. 2016 May;25(5):1417-1427. doi: 10.1007/s00586-015-4325-z. Epub 2016 Feb 23.
4
Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases.
J Invest Dermatol. 2002 Nov;119(5):1096-102. doi: 10.1046/j.1523-1747.2002.19515.x.
5
Clinical Characteristics and Diagnosis of Acute Myeloid Leukemia with CD56-Blastic Plasmacytoid Dendritic Cell Neoplasm.
Clin Lab. 2023 Jun 1;69(6). doi: 10.7754/Clin.Lab.2022.220929.
6
In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.
Haematologica. 2015 Feb;100(2):223-30. doi: 10.3324/haematol.2014.111740. Epub 2014 Nov 7.
7
Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm.
Haematologica. 2017 Nov;102(11):1861-1868. doi: 10.3324/haematol.2017.169326. Epub 2017 Aug 10.
8
T Lymphoblastic Lymphoma Hiding in Mature Plasmacytoid Dendritic Cell Proliferation: A Case Report and Literature Review.
Diagnostics (Basel). 2023 Oct 19;13(20):3248. doi: 10.3390/diagnostics13203248.
9
The expression of transmembrane and soluble CXCL16 and the relation with interferon-alpha secretion in patients with Behçet's disease.
Clin Exp Rheumatol. 2013 May-Jun;31(3 Suppl 77):84-7. Epub 2013 Sep 9.
10
Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia.
Haematologica. 2019 Jul;104(7):1378-1387. doi: 10.3324/haematol.2018.203018. Epub 2018 Dec 6.
本文引用的文献
1
Plasmacytoid Dendritic Cells Mediate CpG-ODN-induced Increase in Survival in a Mouse Model of Lymphangioleiomyomatosis.
Am J Respir Cell Mol Biol. 2024 Nov;71(5):519-533. doi: 10.1165/rcmb.2023-0410OC.
2
Bi-steric mTORC1 inhibitors induce apoptotic cell death in tumor models with hyperactivated mTORC1.
J Clin Invest. 2023 Nov 1;133(21):e167861. doi: 10.1172/JCI167861.
3
mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion.
Nat Commun. 2023 Mar 3;14(1):1214. doi: 10.1038/s41467-023-36881-7.
4
Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma.
Cancer Discov. 2021 Dec 1;11(12):2998-3007. doi: 10.1158/2159-8290.CD-21-0425.
5
Discrepant antitumor efficacies of three CpG oligodeoxynucleotide classes in monotherapy and co-therapy with PD-1 blockade.
Pharmacol Res. 2020 Nov;161:105293. doi: 10.1016/j.phrs.2020.105293. Epub 2020 Nov 8.
6
Adoptive T-Cell Transfer to Treat Lymphangioleiomyomatosis.
Am J Respir Cell Mol Biol. 2020 Jun;62(6):793-804. doi: 10.1165/rcmb.2019-0117OC.
7
Plasmacytoid Dendritic Cells: Development, Regulation, and Function.
Immunity. 2019 Jan 15;50(1):37-50. doi: 10.1016/j.immuni.2018.12.027.
8
A multiprotein supercomplex controlling oncogenic signalling in lymphoma.
Nature. 2018 Aug;560(7718):387-391. doi: 10.1038/s41586-018-0290-0. Epub 2018 Jun 20.
9
TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy.
JCI Insight. 2018 Apr 19;3(8). doi: 10.1172/jci.insight.98674.
10
Lymphangioleiomyomatosis: A Monogenic Model of Malignancy.
Annu Rev Med. 2017 Jan 14;68:69-83. doi: 10.1146/annurev-med-050715-104245.
Zotero 插件